TB Research

Dual β-lactam for treatment of pulmonary <i>Mycobacterium abscessus</i> in a child

Bradford Becken, Khalid M Dousa, John L. Johnson, Steven M. Holland, Robert A. Bonomo

Antimicrobial Agents and Chemotherapy · 2024-05

Abstract

ABSTRACT Treatment of Mycobacterium abscessus infection presents significant challenges, exacerbated by the emergence of macrolide-resistant strains that necessitate the use of multiple antimicrobials in combination and carry the potential for significant toxic effects. Select dual beta-lactam combinations, with or without beta-lactamase inhibitors, have been shown to be highly active in vitro . Herein, we describe a 6-year-old child with underlying mild bilateral lower lobe cylindrical bronchiectatic lung disease who developed pulmonary Mycobacterium abscessus infection and was treated with a multi-drug regimen including two β-lactam antibiotics, achieving both early clinical and microbiological cure. This case highlights the potential benefit of dual β-lactam therapy for the treatment of drug-resistant Mycobacterium abscessus infection.

MeSH terms

  • Mycobacterium abscessus
  • Antibiotics
  • Medicine
  • Bronchiectasis
  • Antimicrobial
  • Microbiology
  • Drug resistance
  • Lung
  • Nontuberculous mycobacteria
  • Regimen
  • Mycobacterium
  • Beta-lactam
  • Mycobacterium avium complex
  • Immunology